Nat Rev Drug Discov 2008, 7:21–39.CrossRef 8. Steven PS: Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit Rev Ther Drug 2002, 19:73–98.CrossRef 9. Bilati U, Mann EA, Doelker E: Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles. Eur J Pharm Biopharm 2005, 59:375–388.CrossRef 10. Jorgensenl L, Moeller EH, Weert V, Nielsen HM, Frokjaer S: Preparing and evaluating delivery systems for proteins. Eur J Pharm Sci 2006, 29:174–182.CrossRef 11. Chi EY, Krishnan
S, Randolph TW, Carpenter JF: Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 2003, 20:1325–1336.CrossRef Ilomastat 12. Wang W: Instability, stabilization,
and formulation of liquid protein pharmaceuticals. Int J Pharm 1999, 185:129–188.CrossRef 13. Fu K, Klibanoy AM, Langer R: Protein stability Temsirolimus solubility dmso in controlled-release systems. Nat Biotechol 2000, 18:24–25.CrossRef 14. Yuan WE, Wu F, Geng Y, Jin T: An effective approach to prepare uniform protein–Zn2+ nanoparticles under mild conditions. Nanotechnology 2007, 18:145601–145608.CrossRef 15. Yuan WE, Wu F, Geng Y, Xu SL, Jin T: Preparation of dextran glassy particles through freezing-induced phase separation. Int J Pharm 2007, 339:76–83.CrossRef 16. Sah H: Protein behavior at the water/methylene chloride interface. J Pharm Sci 1999, 88:1320–1325.CrossRef 17. Sah H: Protein instability toward organic solvent/water emulsification: implications for protein microencapsulation into microspheres. PDA J Pharm Sci Technol 1999, 53:3–10. 18. Huub S, Nicole C: Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 2004, 251:1114–1119. 19. Eun SL, Min JK, Hyeok L, Jung JK: Stabilization of protein encapsulated in poly(lactide- co -glycolide) PAK6 microspheres by novel viscous S/W/O/W method. Int J Pharm 2007, 331:27–37.CrossRef 20. Brian C, Steven B, Jame AW: Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science 1990, 250:1709–1712.CrossRef 21. Johnson OL, Cleland JL, Lee HJ, Charnis M, Duenas E, Jaworowicz
W: A month-long effect from a single injection of microencapsulated human growth hormone. Nat Med 1996, 2:795.CrossRef 22. Brodbeck KJ, Pushpala S, McHugh AJ: Sustained release of human growth hormone from PLGA solution Talazoparib depots. Pharm Res 1999, 16:1825–1829.CrossRef 23. Andreas J, Annice M, Jan A, Linda S, Stephen MS: A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile. Clin Endocrinol 2005, 62:623–627.CrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions FW performed the experiment. LMW and WEY designed the experiments and wrote the manuscript. JS participated in the measurements. ZHZ and TJ provided useful suggestions.